2026 Oncology Drug Development Planning Realities
As we kickoff 2026, here are the operational and strategic realities shaping Q1–Q2 2026 oncology starts. Reality #1: Phase I… [read more]
Read articleYou need the right data, as early as possible, to optimize the results of your oncology drug development efforts. As a specialty oncology CRO, Medelis has the breadth of capabilities, depth of expertise, focus and agility to deliver accurate results – quickly.
For our clients, this means more than completing your trial on time and on budget; it also provides the decision support to determine your next clinical move.






As we kickoff 2026, here are the operational and strategic realities shaping Q1–Q2 2026 oncology starts. Reality #1: Phase I… [read more]
Read articleAt BIO Europe 2025, we spoke with oncology sponsors across Europe and the U.S. about how they’re planning early-phase trials… [read more]
Read articleMedelis, a specialty oncology CRO focused on early-phase clinical trials, will attend BIO Europe 2025 this November in Vienna. CEO… [read more]
Read article